Tyson Will Close Poultry Plants in Virginia and Arkansas That Employ More Than 1,600

Mar 16, 2023

Tyson Foods is closing two facilities that employ more than 1,600 people in an effort to streamline its U.S. poultry business.

The company said Tuesday it plans to close its processing, broiler and hatching operations in Glen Allen, Virginia, and a plant in Van Buren, Arkansas. Both closures are scheduled for May 12.

Tyson said the closures will help it better use all available capacity at remaining plants.

The Springdale, Arkansas-based company said it will work with its 692 employees in Glen Allen and its 969 employees in Van Buren to apply for open positions at other plants.

Tyson has made other efforts to consolidate its operations in recent months. Last October, the company announced it would relocate 1,000 corporate staff from offices in Illinois and South Dakota to Arkansas.

Tyson said operating inefficiencies were partly to blame for its lower-than-expected profit in its fiscal first quarter, which ended Dec. 31. The company said its operating income dropped 68% to $467 million in the period.

Source : usf.edu

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.